logo-loader

Anteo Diagnostics trades higher as it strengthens intellectual property

Published: 12:30 12 Jan 2017 AEDT

patent
Anteo Diagnostics trades higher as it strengthens intellectual property

Anteo owns a patented nanochemistry surface engineering technology.

Recent development work in the application of this technology in the medical device arena discovered a number of new application areas, leading Anteo to establishing a stronger intellectual property position.

Two patent applications have progressed to the international patent cooperation treaty (PCT) stage, one has progressed to the national phase and one patent application has been recently filed.

Tamara Mills, COO, commented: “With a background in medical device development and commercialisation, I have taken a particular interest in how Anteo’s nanochemistry can be applied to medical devices.”

“Recent development work in the application of Anteo’s technology in the medical device arena discovered a number of new application areas, leading Anteo to establishing a stronger intellectual property position in this exciting field.

“We are excited by the recent progress we have seen in moving our patent applications through the examination process and in the filing of new applications.”


Patent application progression

In late November 2016, a patent application describing controlled competitive exchange progressed to the PCT phase.

Additionally, in December 2016, Anteo received notice of progress in the examination of two additional patent applications.

The Anteo intellectual property position in the medical devices segment has been further strengthened by the filing of a provisional patent application, in Oct 2016, to cover novel applications of Anteo technology relating to the development of coatings on flexible electrodes useful in sensors and active implantable devices.


Progressing from energy space to medical space

One of the new development areas being explored, flexible electrodes, bridges Anteo’s intellectual property and expertise in the energy space to the medical device space.

Anteo is actively seeking development partners in the application of this breakthrough technology in neural prosthetic devices, medical devices that can substitute a motor, sensory or cognitive modality that might have been damaged as a result of an injury or a disease, such as cochlear implants or retina implants.


Background

Anteo Group is a global nano-chemistry technology and medical supply group, developing, commercialising, manufacturing and distributing products.

These products are targeted at the life sciences, IVD, point of care, medical devices and energy markets.

Anteo completed the acquisition of DIAsource in January, 2016 for  €15.4 million, which now forms the nucleus of the IVD and life sciences division.

Importantly, Anteo owns a patented metal ion polymer technology platform which creates strong and stable binding of antibodies to a variety of surfaces.

Anteo’s surface binding technology is a core feature in many of Anteo's products and provides its partners with a competitive advantage in the market.

Anteo is also applying its technology to the medical device market and has developed a proprietary nano primer/coating technology.

Further, recent work in the application of the technology to the development of silicon anodes to improve stability and increase cycle life shows promise in the industry sector of lithium-ion batteries.

Australian Strategic Materials signs US$600 million LoI

Rowena Smith, CEO and managing director of Australian Strategic Materials Ltd (ASX:ASM, OTC:ASMMF), joins Jonathan Jackson in the Proactive studio to discuss the company’ s Dubbo Project, in Central West New South Wales. This project aims to extract and process critical minerals and rare earth...

6 hours, 46 minutes ago